DNA vaccines encoding li-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency

被引:76
作者
Hung, Chien-Fu
Tsai, Ya-Chea
He, Liangmei
Wu, T-C
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA
关键词
D O I
10.1038/sj.mt.6300121
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
It is now clear that CD4(+) T cells play a crucial role in the generation of CD8(+) T effector and memory T-cell immune responses. In this study, we enhanced the CD4(+) T-cell immune responses in mice by constructing a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii peptide (CLIP) region is replaced with a CD4(+) T-helper epitope, PADRE (Ii-PADRE) (invariant Pan HLA-DR reactive epitope). C57BL/6 mice vaccinated with DNA encoding Ii-PADRE showed significantly greater PADRE-specific CD4(+) T-cell immune responses than mice vaccinated with DNA encoding the Ii chain alone (Ii DNA). More important, administration of DNA encoding human papillomavirus (HPV) E6 or E7 antigen with DNA encoding Ii-PADRE led to significantly stronger E6- or E7-specific CD8(+) T-cell immune responses and more potent protective and therapeutic anti-tumor effects against an E6/E7-expressing tumor model in mice than administration of E6 or E7 DNA with Ii DNA. Overall, our data indicate that administration of DNA vaccines with Ii-PADRE DNA represents an effective approach to enhancing the generation of CD4(+) T cells and eliciting stronger antigen-specific CD8(+) T-cell immune responses. Therefore, this strategy may be expected to have significant potential for clinical translation.
引用
收藏
页码:1211 / 1219
页数:9
相关论文
共 33 条
[11]   DNA-based immunization by in vivo transfection of dendritic cells [J].
Condon, C ;
Watkins, SC ;
Celluzzi, CM ;
Thompson, K ;
Falo, LD .
NATURE MEDICINE, 1996, 2 (10) :1122-1128
[12]   The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells [J].
Fujii, S ;
Senju, S ;
Chen, YZ ;
Ando, M ;
Matsushita, S ;
Nishimura, Y .
HUMAN IMMUNOLOGY, 1998, 59 (10) :607-614
[13]   Viral recombinant vaccines to the E6 and E7 antigens of HPV-16 [J].
He, Z ;
Wlazlo, AP ;
Kowalczyk, DW ;
Cheng, J ;
Xiang, ZQ ;
Giles-Davis, W ;
Ertl, HCJ .
VIROLOGY, 2000, 270 (01) :146-161
[14]   Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope [J].
Huang, CH ;
Peng, S ;
He, L ;
Tsai, YC ;
Boyd, DAK ;
Hansen, TH ;
Wu, TC ;
Hung, CF .
GENE THERAPY, 2005, 12 (15) :1180-1186
[15]  
Hung CF, 2003, CURR OPIN MOL THER, V5, P20
[16]   The central role of CD4+ T cells in the antitumor immune response [J].
Hung, K ;
Hayashi, R ;
Lafond-Walker, A ;
Lowenstein, C ;
Pardoll, D ;
Levitsky, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368
[17]  
Lin KY, 1996, CANCER RES, V56, P21
[18]  
Malcherek G, 1998, EUR J IMMUNOL, V28, P1524, DOI 10.1002/(SICI)1521-4141(199805)28:05<1524::AID-IMMU1524>3.0.CO
[19]  
2-T
[20]   Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity [J].
Marzo, AL ;
Kinnear, BF ;
Lake, RA ;
Frelinger, JJ ;
Collins, EJ ;
Robinson, BWS ;
Scott, B .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6047-6055